Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Dec 1:2.
doi: 10.3402/jmahp.v2.25302. eCollection 2014.

Pharmaceutical market access in emerging markets: concepts, components, and future

Affiliations
Review

Pharmaceutical market access in emerging markets: concepts, components, and future

Anuj Kumar et al. J Mark Access Health Policy. .

Abstract

This article intends to consolidate the concepts of pharmaceutical market access and highlight its growing importance in emerging markets. Market access has gained considerable attention worldwide as countries try to contain their escalating healthcare expenditures amidst the global economic slowdown. This has resulted in governments adopting stricter measures for new product approval. Thus, pharmaceutical companies are finding it increasingly difficult to successfully address the specific challenges posed by various government and regulatory agencies and stakeholders. There is an increasing need to establish market access functions, especially in emerging markets, where the complex, dynamic healthcare landscape confounds product approval and uptake. Moreover, emerging markets are the engines of growth today, and, thus, performing in these markets is critical for the majority of pharmaceutical companies. To address the challenges posed by regulatory agencies and diverse stakeholders, a customized market access strategy is the need of the hour. A market access framework with specific tools and tactics will help companies to plan, implement, and monitor stakeholder engagement activities.

Keywords: developed markets; emerging markets; escalating healthcare cost; market access framework; pharmaceutical market access; pricing and reimbursement; stakeholders.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Lataillade TD, Billy A. Market access in Europe: An exclusive survey on biopharmaceutical industry trends. Cegedim Relationship Management; 2010. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/EU_Market_Access_Survey_Whit... [cited 14 May 2014]
    1. Hulten EV, Lataillade TD. Market Access in Europe 2011. Cegedim Relationship Management; 2011. Available from: http://crm.cegedim.com/Docs_Whitepaper/Data/EU_Market_Access_Survey_Rpt_... [cited 30 April 2014]
    1. Wang L, Richardson R. Planning for change: Adapting to shifts in the global market access landscape. Campbell Alliance; No date. Available from: http://www.campbellalliance.com/articles/Campbell_Alliance_Global_Market... [cited 14 June 2014]
    1. Mikkelsen JS. Market access for medical technology & pharmaceutical companies: An organizational priority in times of economic austerity and reform. 2012. Available from: http://um.dk/en/~/media/USA/Market Access for Medical Technology Pharmac... [cited 24 April 2014]
    1. Forcellina A, Akannac C. Managing talent to meet pharma's next great challenge: Global market access, 2013. Egon Zehnder International; 2013. Available from: http://www.egonzehnder.com/files/managing_talent_to_meet_pharmas_next_gr... [cited 17 October 2014]

LinkOut - more resources